Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2048 - Discordance of EGFR mutation status between primary lung adenocarcinomas and corresponding metastatic tumors and the sensitivity to EGFR tyrosine kinase inhibitors

Date

08 Oct 2016

Session

Poster Display

Presenters

Hye Sook Han

Citation

Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383

Authors

H.S. Han1, J. Yang2, M.K. Choi2, J. Kwon2, K.H. Lee1, O. Lee3

Author affiliations

  • 1 Department Of Internal Medicine, College of Medicine, Chungbuk National University, 218644 - Cheongju/KR
  • 2 Department Of Internal Medicine, Chungbuk National University Hospital, 28644 - Cheong-ju/KR
  • 3 Department Of Pathology, College of Medicine, Chungbuk National University, 28644 - Cheong-ju/KR
More

Resources

Abstract 2048

Background

A considerable proportion of non-small cell lung cancer has showed a discrepancy in epidermal growth factor receptor (EGFR) mutations between matched primary and metastatic tumors. The aim of this study was to clarify the distribution of EGFR mutations in primary lung adenocarcinomas and corresponding metastatic tumors with highly sensitive method of detecting EGFR mutations and to identify a better predictive marker of the response to EGFR tyrosine kinase inhibitors.

Methods

We performed peptide nucleic acid-mediated real-time polymerase chain reaction clamping to identify EGFR mutations in paired primary lung adenocarcinomas and metastatic tumors in 24 patients who were treated with EGFR tyrosine kinase inhibitors, but had not received EGFR tyrosine kinase inhibitors before both primary and metastatic tissues were sampled.

Results

EGFR mutations were detected in 20 primary lung adenocarcinomas (83.3%) and in 19 corresponding metastatic tumors (79.2%). EGFR mutations showed a discordance rate of 20.8% (5 of 24 patients) between primary lung adenocarcinomas and corresponding metastatic tumors. Three patients with EGFR-mutated primary tumors lost their mutations in the metastatic tumors and showed no response to EGFR tyrosine kinase inhibitors. Two patients had EGFR mutations in the metastatic tumors but not in the primary lung adenocarcinomas and experienced a partial response to EGFR tyrosine kinase inhibitors.

Conclusions

EGFR mutations were discordant between matched primary and metastatic tumors before EGFR tyrosine kinase inhibitor therapy in a significant portion of lung adenocarcinomas. Our findings suggest that the EGFR mutation status of metastatic tumors in patients with metastatic lung adenocarcinoma is a predictive marker of the response to EGFR tyrosine kinase inhibitors. EGFR tyrosine kinase inhibitors are used to treat metastatic disease, therefore, a more aggressive pursuit of tissue sampling from metastatic lesions may be indicated to accurately determine EGFR mutations for planning of the use of EGFR tyrosine kinase inhibitors to treat metastatic lung adenocarcinoma.

Clinical trial identification

Legal entity responsible for the study

College of Medicine, Chungbuk National University Chungbuk National University Hospital

Funding

College of Medicine, Chungbuk National University Chungbuk National University Hospital

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings